Lens Marko
King's College, St Thomas' Hospital, Genetic Epidemiology Unit, Lambeth Palace Road, London SE1 7EH, UK.
Expert Opin Biol Ther. 2008 Mar;8(3):315-23. doi: 10.1517/14712598.8.3.315.
Melanoma is a tumour that is usually resistant to systemic therapy. Since it has been considered to be a highly immunogenic tumour, it has become an excellent target for the active specific immunotherapy. Vaccine therapy represents a novel approach to the treatment of melanoma.
To evaluate different vaccines tested in stage III and/or IV melanoma patients.
Systematic review of the published evidence on vaccine therapy in melanoma.
Melanoma vaccines can be classified into six groups: whole-cell vaccines, dendritic cell vaccines, peptide vaccines, ganglioside vaccines, DNA vaccines and viral vectors. The main characteristics of these vaccines including their advantages and disadvantages and the results from conducted trials are presented. Clinical responses to melanoma vaccines are still poor and currently there is no melanoma vaccine with a proven efficacy.
Vaccine therapy still remains an experimental therapy in patients with metastatic melanoma. Further research is required although a future therapy for advanced melanoma is probably a multimodal approach including vaccines, adjuvants and negative co-stimulatory blockade.
黑色素瘤是一种通常对全身治疗耐药的肿瘤。由于其被认为是一种高度免疫原性的肿瘤，它已成为主动特异性免疫治疗的一个极佳靶点。疫苗治疗代表了一种治疗黑色素瘤的新方法。
评估在III期和/或IV期黑色素瘤患者中测试的不同疫苗。
对已发表的关于黑色素瘤疫苗治疗的证据进行系统评价。
黑色素瘤疫苗可分为六类：全细胞疫苗、树突状细胞疫苗、肽疫苗、神经节苷脂疫苗、DNA疫苗和病毒载体。介绍了这些疫苗的主要特点，包括其优缺点以及所进行试验的结果。黑色素瘤疫苗的临床反应仍然较差，目前尚无经证实有效的黑色素瘤疫苗。
疫苗治疗在转移性黑色素瘤患者中仍然是一种实验性治疗方法。尽管晚期黑色素瘤未来的治疗可能是一种包括疫苗、佐剂和负性共刺激阻断的多模式方法，但仍需要进一步研究。
